We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-6.76%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.35B
AUM Growth
-$253M
Cap. Flow
-$52M
Cap. Flow %
-2.22%
Top 10 Hldgs %
44.73%
Holding
154
New
14
Increased
27
Reduced
18
Closed
11

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$16.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.7M
3
JNJ icon
Johnson & Johnson
JNJ
+$12.2M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$11M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$10.1M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$27.4M
2
A icon
Agilent Technologies
A
+$21.7M
3
CPHD
Cepheid Inc
CPHD
+$17.6M
4
LLY icon
Eli Lilly
LLY
+$16.4M
5
UNH icon
UnitedHealth
UNH
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 90.58%
2 Real Estate 3.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$163B
$181M 7.72%
2,530,131
-130,000
-5% -$9.66M
CELG
2
DELISTED
Celgene Corp
CELG
$163M 6.95%
1,409,889
-74,200
-5% -$8.26M
BIIB icon
3
Biogen
BIIB
$30.7B
$152M 6.49%
537,350
+55,317
+11% +$16.4M
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$97.4M 4.15%
795,905
+31,900
+4% +$3.9M
AGN
5
DELISTED
Allergan plc
AGN
$91.2M 3.88%
434,086
– –
INCY icon
6
Incyte
INCY
$24.9B
$88.3M 3.76%
880,461
– –
VRTX icon
7
Vertex Pharmaceuticals
VRTX
$122B
$76.1M 3.24%
1,033,503
– –
MRK icon
8
Merck
MRK
$321B
$70.5M 3.01%
1,255,870
-50,354
-4% -$2.95M
REGN icon
9
Regeneron Pharmaceuticals
REGN
$77.4B
$68.9M 2.93%
187,666
+33,400
+22% +$12.7M
ABT icon
10
Abbott
ABT
$183B
$60.8M 2.59%
1,583,700
+205,100
+15% +$8.13M
JNJ icon
11
Johnson & Johnson
JNJ
$617B
$51.1M 2.18%
443,212
+105,900
+31% +$12.2M
BMRN icon
12
BioMarin Pharmaceuticals
BMRN
$11.7B
$47.4M 2.02%
572,645
-137,500
-19% -$11.8M
AMGN icon
13
Amgen
AMGN
$209B
$47M 2%
321,640
– –
MDT icon
14
Medtronic
MDT
$110B
$44.4M 1.89%
623,030
– –
VTRS icon
15
Viatris
VTRS
$20.7B
$43.3M 1.85%
1,135,552
– –
SHPG
16
DELISTED
Shire pic
SHPG
$39.4M 1.68%
231,413
– –
UNH icon
17
UnitedHealth
UNH
$383B
$39.4M 1.68%
245,920
-85,180
-26% -$12.7M
PFE icon
18
Pfizer
PFE
$142B
$37.2M 1.59%
1,208,610
– –
LLY icon
19
Eli Lilly
LLY
$1.03T
$36.3M 1.55%
493,100
-220,667
-31% -$16.4M
JAZZ icon
20
Jazz Pharmaceuticals
JAZZ
$16.2B
$36.1M 1.54%
331,411
– –
HUM icon
21
Humana
HUM
$44B
$33.6M 1.43%
164,800
– –
CVS icon
22
CVS Health
CVS
$134B
$32.5M 1.38%
411,891
– –
ILMN icon
23
Illumina
ILMN
$31B
$31.6M 1.34%
253,464
– –
TEVA icon
24
Teva Pharmaceuticals
TEVA
$41.2B
$28.6M 1.22%
788,958
– –
MDCO
25
DELISTED
Medicines Co
MDCO
$26.2M 1.12%
771,638
+207,200
+37% +$7.35M
1
2 3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, Tekla Capital Management held 154 positions worth $2.35B, down 9.7% from $2.6B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Tekla Capital Management's Q4 2016 filing shows 14 new, 27 increased, 18 reduced and 11 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 179,000 shares worth $10.6M. The largest sale was Alkermes, an estimated $27.4M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2016 buy was State Street SPDR S&P Biotech ETF: 179,000 shares worth $10.6M.
  • Tekla Capital Management added most to Biogen in Q4 2016, an estimated $16.4M increase.
  • Tekla Capital Management's biggest Q4 2016 reduction was Eli Lilly, cutting an estimated $16.4M.
  • Tekla Capital Management fully exited Alkermes in Q4 2016, selling an estimated $27.4M.
  • Tekla Capital Management's ten largest holdings make up 45% of its $2.35B portfolio in Q4 2016.
  • Tekla Capital Management opened 14 new positions and closed 11 in Q4 2016.
  • Tekla Capital Management's portfolio value fell 9.7% quarter-over-quarter to $2.35B.

Based on Tekla Capital Management's 13F filing for Q4 2016, filed 13 Feb 2017.